SFDA approves China Medical Technologies' SPR-based HPV-DNA chip

NewsGuard 100/100 Score

China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has received approval for its SPR-based HPV-DNA chip (the "HPV Chip") from the State Food and Drug Administration of China (the "SFDA").

Human papillomavirus ("HPV") is a common virus that infects the skin and mucous membranes of humans and causes various kinds of warts as well as cervical cancer. Over 100 HPV subtypes have been identified, in which 16 high risk HPV subtypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 81) may lead to the development of cervical cancer and 8 low risk HPV subtypes (6, 11, 40, 42, 43, 44, 54, 70) may lead to genital warts. The HPV Chip can detect the high risk genotypes as well as the low risk genotypes by placing a patient's sample on one chip and processing the chip by the Company's fully-automated SPR analyzer. The HPV Chip can also distinguish multiple HPV infection as well as determine the viral load which are all important for physicians to recommend treatment for patients.

According to the World Health Organization, China has a population of about 500 million women ages 15 years and older who are under the risk of cervical cancer. According to the Ministry of Health in China, approximately 70 million gynecological check-ups were conducted in 2008.


China Medical Technologies, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
LMU researchers shed light on DNA repair mechanisms in Cockayne syndrome